Synonym
Polythiazide; NSC-108161; P-2525; NSC108161; P2525; NSC 108161; P 2525; Nephril; Renese
IUPAC/Chemical Name
6-chloro-2-methyl-3-(((2,2,2-trifluoroethyl)thio)methyl)-3,4-dihydro-2H-benzo[e][1,2,4]thiadiazine-7-sulfonamide 1,1-dioxide
InChi Key
CYLWJCABXYDINA-UHFFFAOYSA-N
InChi Code
InChI=1S/C11H13ClF3N3O4S3/c1-18-10(4-23-5-11(13,14)15)17-7-2-6(12)8(24(16,19)20)3-9(7)25(18,21)22/h2-3,10,17H,4-5H2,1H3,(H2,16,19,20)
SMILES Code
O=S(C1=C(Cl)C=C(C2=C1)NC(CSCC(F)(F)F)N(C)S2(=O)=O)(N)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
439.87
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Agatonovic-Kustrin S, Zivanovic LJ. Spectrophotometric study of polythiazide-palladium (II) complex. J Pharm Biomed Anal. 1989;7(12):1559-64. PubMed PMID: 2490543.
2: Dokladalova J, Coco SJ, Lemke PR, Quercia GT, Korst JJ. Determination of polythiazide and prazosin in human plasma by high-performance liquid chromatography. J Chromatogr. 1981 Jun 12;224(1):33-41. PubMed PMID: 7263818.
3: Hobbs DC, Twomey TM. Kinetics of polythiazide. Clin Pharmacol Ther. 1978 Feb;23(2):241-6. PubMed PMID: 620486.
4: TALSO PJ, CARBALLO AJ. POLYTHIAZIDE IN THE MANAGEMENT OF HYPERTENSIVE DISEASE. II. COMPARISON OF THE EFFECTS OF POLYTHIAZIDE AND RESERPINE IN THE MANAGEMENT OF HYPERTENSION IN ABULATORY PATIENTS. Curr Ther Res Clin Exp. 1964 Mar;6:169-79. PubMed PMID: 14131417.
5: Wang L, Ma C, Wipf P, Liu H, Su W, Xie XQ. TargetHunter: an in silico target identification tool for predicting therapeutic potential of small organic molecules based on chemogenomic database. AAPS J. 2013 Apr;15(2):395-406. doi: 10.1208/s12248-012-9449-z. Epub 2013 Jan 5. PubMed PMID: 23292636; PubMed Central PMCID: PMC3675739.
6: Gordon AJ, Woeltjen AE. Treatment of Essential hypertension with single daily doses of a prazosin-polythiazide combination: a multicentre study with Minizide. J Int Med Res. 1981;9(5):303-8. PubMed PMID: 7297754.
7: Oh MS, Carroll HJ, Cruz WM, Whang ES, Lejano RF. Treatment of hypertension with a combination of prazosin and polythiazide. Postgrad Med. 1975 Nov;Spec No:77-80. PubMed PMID: 1105488.
8: Kuokkanen K, Mattila MJ. Demonstration of an additive antihypertensive effect of prazosin and polythiazide in out-patient. Curr Ther Res Clin Exp. 1975 May;17(5):431-6. PubMed PMID: 805026.
9: Wojdylo L, Zatónska I. [Observations on the action of polythiazide in congestive heart failure. I. The influence of polythiazide on the diuresis, glomerular filtration, excretion of some electrolytes in urine and their levels in serum, and on the general condition of patients]. Ann Univ Mariae Curie Sklodowska Med. 1970;25:259-64. Polish. PubMed PMID: 5525324.
10: Guevara J, Collet-Velasco H, Velasco M. Antihypertensive effect of prazosin alone and its combination with polythiazide in patients with essential hypertension. Curr Ther Res Clin Exp. 1976 Dec;20(6):751-6. PubMed PMID: 827421.
